These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

182 related items for PubMed ID: 1355090

  • 1. An oncogenic point mutation confers high affinity ligand binding to the neu receptor. Implications for the generation of site heterogeneity.
    Ben-Levy R, Peles E, Goldman-Michael R, Yarden Y.
    J Biol Chem; 1992 Aug 25; 267(24):17304-13. PubMed ID: 1355090
    [Abstract] [Full Text] [Related]

  • 2. Biochemical comparisons of the normal and oncogenic forms of insect cell-expressed neu tyrosine kinases.
    Guy PM, Carraway KL, Cerione RA.
    J Biol Chem; 1992 Jul 15; 267(20):13851-6. PubMed ID: 1352772
    [Abstract] [Full Text] [Related]

  • 3. Receptor functions and ligand-dependent transforming potential of a chimeric kit proto-oncogene.
    Lev S, Yarden Y, Givol D.
    Mol Cell Biol; 1990 Nov 15; 10(11):6064-8. PubMed ID: 1700279
    [Abstract] [Full Text] [Related]

  • 4. Oncogenic forms of the neu/HER2 tyrosine kinase are permanently coupled to phospholipase C gamma.
    Peles E, Levy RB, Or E, Ullrich A, Yarden Y.
    EMBO J; 1991 Aug 15; 10(8):2077-86. PubMed ID: 1676673
    [Abstract] [Full Text] [Related]

  • 5. Phosphorylation process induced by epidermal growth factor alters the oncogenic and cellular neu (NGL) gene products.
    Kokai Y, Dobashi K, Weiner DB, Myers JN, Nowell PC, Greene MI.
    Proc Natl Acad Sci U S A; 1988 Aug 15; 85(15):5389-93. PubMed ID: 2899889
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. A chimeric EGF-R-neu proto-oncogene allows EGF to regulate neu tyrosine kinase and cell transformation.
    Lehväslaiho H, Lehtola L, Sistonen L, Alitalo K.
    EMBO J; 1989 Jan 15; 8(1):159-66. PubMed ID: 2565807
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The multiple endocrine neoplasia type 2B point mutation alters long-term regulation and enhances the transforming capacity of the epidermal growth factor receptor.
    Pandit SD, Donis-Keller H, Iwamoto T, Tomich JM, Pike LJ.
    J Biol Chem; 1996 Mar 08; 271(10):5850-8. PubMed ID: 8621456
    [Abstract] [Full Text] [Related]

  • 12. Oncogenic activation of p185neu stimulates tyrosine phosphorylation in vivo.
    Stern DF, Kamps MP, Cao H.
    Mol Cell Biol; 1988 Sep 08; 8(9):3969-73. PubMed ID: 2464744
    [Abstract] [Full Text] [Related]

  • 13. The effects of the normal and oncogenic forms of the neu tyrosine kinase, and the corresponding forms of an immunoglobulin E receptor/neu tyrosine kinase fusion protein, on Xenopus oocyte maturation.
    Narasimhan V, Hamill O, Cerione RA.
    FEBS Lett; 1992 Jun 01; 303(2-3):164-8. PubMed ID: 1351469
    [Abstract] [Full Text] [Related]

  • 14. Enhancement of tyrosine kinase activity of the Drosophila epidermal growth factor receptor homolog by alterations of the transmembrane domain.
    Wides RJ, Zak NB, Shilo BZ.
    Eur J Biochem; 1990 May 20; 189(3):637-45. PubMed ID: 1972062
    [Abstract] [Full Text] [Related]

  • 15. A single amino acid substitution is sufficient to modify the mitogenic properties of the epidermal growth factor receptor to resemble that of gp185erbB-2.
    Di Fiore PP, Helin K, Kraus MH, Pierce JH, Artrip J, Segatto O, Bottaro DP.
    EMBO J; 1992 Nov 20; 11(11):3927-33. PubMed ID: 1356764
    [Abstract] [Full Text] [Related]

  • 16. Epidermal growth factor (EGF) modulation of feline sarcoma virus fms tyrosine kinase activity, internalization, degradation, and transforming potential in an EGF receptor/v-fms chimera.
    Riedel H.
    J Virol; 1994 Jan 20; 68(1):411-24. PubMed ID: 8254751
    [Abstract] [Full Text] [Related]

  • 17. A chimeric EGFR/neu receptor in functional analysis of the neu oncoprotein.
    Lehtola L, Lehväslaiho H, Koskinen P, Alitalo K.
    Acta Oncol; 1992 Jan 20; 31(2):147-50. PubMed ID: 1352454
    [Abstract] [Full Text] [Related]

  • 18. A subdomain in the transmembrane domain is necessary for p185neu* activation.
    Cao H, Bangalore L, Bormann BJ, Stern DF.
    EMBO J; 1992 Mar 20; 11(3):923-32. PubMed ID: 1347745
    [Abstract] [Full Text] [Related]

  • 19. Demonstration of ligand-dependent signaling by the erbB-3 tyrosine kinase and its constitutive activation in human breast tumor cells.
    Kraus MH, Fedi P, Starks V, Muraro R, Aaronson SA.
    Proc Natl Acad Sci U S A; 1993 Apr 01; 90(7):2900-4. PubMed ID: 8464905
    [Abstract] [Full Text] [Related]

  • 20. Ligand and p185c-neu density govern receptor interactions and tyrosine kinase activation.
    Samanta A, LeVea CM, Dougall WC, Qian X, Greene MI.
    Proc Natl Acad Sci U S A; 1994 Mar 01; 91(5):1711-5. PubMed ID: 7907421
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.